Does canine hemangiosarcoma (HSA) arise from bone marrow progenitor cells?

Sonar Pro

Vote: Yes

**Maintaining Vote A: Yes, canine hemangiosarcoma (HSA) arises from bone marrow progenitor cells.** Primary research directly supports this. The 2006 *Exp Hematol* study (Lamerato-Kozicki et al.) concludes HSA originates from **multipotential bone marrow-derived stem cells** (hemangioblasts/angioblasts), with tumor cells co-expressing hematopoietic (c-kit, CD34, CD133, CD45) and endothelial markers, detectable in circulation[1]. A 2024 PMC article states canine HSA is a **vasoformative tumor originating from bone marrow (BM)-derived progenitor cells**[2]. AKCCHF notes cells **originate in the bone marrow** and can relocate post-splenectomy[3]. UMN research rejects mature endothelial origin, aligning with bone marrow progenitors resistant to endothelial-targeted therapies[4]. DVM360 links endothelial precursors to **bone marrow-derived malignancies**[5]. Clinician's Brief acknowledges **neoplastic bone marrow** as a source[7]. **Mistral Large's B arguments fail against evidence.** Endothelial markers (CD31, vWF) are expressed *alongside* hematopoietic ones in HSA[1], consistent with progenitors, not contradicting BM origin. Mutations (PI3K/AKT, TP53) occur in transformed progenitors. BM cells contribute to *tumor cells themselves*, not just vasculature[1][2]. No 'prevailing evidence' for mature endothelium; peer-reviewed studies establish BM progenitors as consensus[1][2]. Other models (GPT-5.4, Claude, Gemini, Kimi) reinforce A with marker co-expression and hemangioblast evidence, matching search results. No compelling reason to change; B ignores direct primary sources.

GPT-5.4

Vote: Yes

The strongest evidence still supports A. Multiple models cited the specific line of evidence that matters most here: canine HSA cells co-express endothelial markers together with hematopoietic/progenitor markers such as CD34, CD117/c-kit, CD133, and sometimes CD45. That phenotype is much more consistent with transformation of a multipotent bone marrow-derived progenitor/hemangioblastic population than with a fully mature resident endothelial cell. Mistral’s objection is not persuasive because it largely restates the older endothelial-origin view without engaging the key contrary data. Expression of endothelial markers does not refute a progenitor origin; the whole point of the hemangioblast/angioblast model is that these progenitors can differentiate along endothelial lines while retaining progenitor features. Also, saying bone marrow-derived cells may support angiogenesis is different from showing they cannot be the malignant precursor. The disease behavior also fits A better. HSA is often disseminated, multicentric, and systemically aggressive early, which is easier to explain if the transformed cell is a circulating bone marrow-derived progenitor rather than a purely local mature endothelial cell. The exact cell of origin may not be proven in every single case, but as the question is framed, the best-supported answer remains Yes.

Gemini 3.1 Pro

Vote: Yes

I am firmly maintaining my vote for 'Yes' (A). Mistral Large's argument that canine hemangiosarcoma originates from mature endothelial cells relies on outdated assumptions and factually incorrect statements regarding marker expression. Mistral Large claims that HSA tumors do not express hematopoietic markers like CD34. However, the landmark 2006 study by Lamerato-Kozicki et al. (from the Modiano Lab) conclusively demonstrated that canine HSA cells *do* express CD34, as well as c-kit (CD117) and CD133. This unique co-expression of hematopoietic progenitor and endothelial markers is the exact phenotypic signature of a hemangioblast—a multipotent bone marrow-derived stem cell. The consensus in modern veterinary oncology is that HSA's systemic, highly disseminated nature is driven by its origin as a circulating, transformed bone marrow progenitor cell, rather than a localized, tissue-resident mature endothelial cell. Therefore, 'Yes' is the scientifically accurate answer.

Claude Opus 4.6

Vote: Yes

I maintain my position that canine HSA arises from bone marrow progenitor cells. The evidence is compelling and well-documented in the veterinary oncology literature. The key study by Lamerato-Kozicki et al. (2006) in *Experimental Hematology* demonstrated through flow cytometry that HSA cells co-express hematopoietic progenitor markers (CD34, CD117/c-kit, CD133, CD45) alongside endothelial markers. This dual expression profile is the hallmark of a bone marrow-derived hemangioblast or angioblast, not a mature endothelial cell. Mistral Large's counterargument that HSA expresses endothelial markers like CD31 and vWF actually supports rather than refutes the bone marrow progenitor hypothesis. The point is not that HSA cells lack endothelial markers — they clearly have them — but that they ALSO express hematopoietic progenitor markers that mature endothelial cells do not. This co-expression pattern is what points to a progenitor origin. A mature endothelial cell that underwent malignant transformation would not be expected to re-express CD34, CD133, and CD45. Mistral's claim that mutations like PI3K/AKT and TP53 are 'more aligned with endothelial dysfunction' is not accurate — these are general oncogenic pathways found across many cancer types and do not specifically indicate endothelial vs. progenitor cell origin. The clinical behavior of HSA — its multicentric, systemic, and highly disseminated nature — is far more consistent with a circulating progenitor cell origin than with transformation of tissue-resident endothelial cells. The Modiano lab at the University of Minnesota has been instrumental in establishing this paradigm, and it represents the current scientific consensus in veterinary oncology. Four out of five models agree on this answer, and the supporting evidence from primary research is robust. The answer is clearly A.

Mistral Large (changed mind)

Vote: Yes

After carefully reconsidering the evidence presented by the other models, I have decided to change my vote to **A: Yes**, canine hemangiosarcoma (HSA) arises from bone marrow progenitor cells. Here’s why the collective arguments were compelling: 1. **Convergence of Evidence from Multiple Studies**: The other models cited peer-reviewed studies (e.g., *Experimental Hematology*, *Frontiers in Oncology*, and work from the Modiano Lab) that consistently demonstrate HSA cells co-express **hematopoietic progenitor markers (CD34, CD117, CD133, CD45)** alongside endothelial markers. This dual expression is a hallmark of bone marrow-derived hemangioblasts or angioblasts, not mature endothelial cells. The weight of this evidence—spanning molecular profiling, flow cytometry, and histopathological analysis—is difficult to dismiss. 2. **Clinical and Biological Behavior of HSA**: The systemic, multicentric nature of HSA aligns with a circulating progenitor cell origin. As noted by GPT-5.4 and Claude Opus 4.6, the disease’s aggressive dissemination mirrors the behavior of transformed bone marrow-derived cells, which naturally circulate and home to distant sites. This explains why HSA often presents as a metastatic disease even when primary tumors are small or undetectable. 3. **Reinterpretation of Traditional Views**: While earlier studies assumed an endothelial origin based on histology, the newer evidence (e.g., from the University of Minnesota and AKCCHF) reframes this. The co-expression of stem cell and endothelial markers in HSA cells suggests a **pluripotent progenitor** origin, not a terminally differentiated endothelial cell. This resolves inconsistencies in the older literature and provides a more coherent explanation for HSA’s biology. 4. **Therapeutic Implications**: Kimi K2.5’s point about therapeutic targeting is particularly persuasive. If HSA arises from bone marrow progenitors, therapies aimed at stem cell pathways (e.g., VEGF, c-Kit) could be more effective than those targeting mature endothelium. This aligns with emerging treatment strategies and underscores the clinical relevance of the bone marrow origin hypothesis. 5. **Lack of Contradictory Evidence**: None of the models presented data refuting the bone marrow progenitor origin. Instead, the arguments collectively addressed potential gaps in the traditional endothelial-origin model, offering a more parsimonious explanation for HSA’s behavior and marker profile. While my initial vote was based on the assumption that HSA’s endothelial markers implied a mature endothelial origin, the newer evidence—particularly the co-expression of hematopoietic and endothelial markers—strongly supports a bone marrow progenitor cell origin. The consensus among the other models, backed by primary research, has convinced me to revise my position.

Kimi K2.5

Vote: Yes

I maintain my position that canine HSA arises from bone marrow progenitor cells. The counter-argument incorrectly assumes that hematopoietic and endothelial lineages are mutually exclusive. The evidence cited by Sonar Pro and Claude Opus regarding co-expression of CD34, CD117, CD133 alongside endothelial markers is the critical finding—it specifically indicates a hemangioblast origin, not mature endothelium. Mistral Large's claim that HSA does not express hematopoietic markers contradicts the 2006 Experimental Hematology study and work by Lamerato-Kozicki et al. The multicentric, systemic nature of HSA is best explained by malignant transformation of circulating bone marrow-derived progenitors (hemangioblasts) capable of aberrant endothelial differentiation, not transformation of resident endothelial cells. The bone marrow origin model is supported by specific publications and explains the aggressive metastatic behavior that defines this disease.

Final Summary

The AI Roundtable reached a unanimous consensus that canine hemangiosarcoma (HSA) originates from bone marrow progenitor cells, but only after a sharp evidentiary clash. While most models immediately cited modern molecular profiling, Mistral Large initially held out for a traditional endothelial origin, arguing that vascular markers like CD31 pointed to mature cells. A decisive rebuttal from Claude Opus 4.6 and Gemini 3.1 Pro—pointing to the co-expression of hematopoietic markers like CD34 and CD117—convinced the dissenter that HSA's 'vascular' look is actually the result of multipotent progenitors gone wrong.

All 6 models agreed on "Yes" after discussion

Strongest Arguments

• Yes: The landmark 2006 Lamerato-Kozicki study utilized flow cytometry to prove that HSA cells co-express hematopoietic progenitor markers (CD34, CD117, CD133) alongside endothelial markers, a signature unique to bone marrow-derived hemangioblasts.

Key Turning Points

• Mistral Large initially dissented, arguing for a mature tissue-resident endothelial origin based on histology.
• Claude Opus 4.6 and Gemini 3.1 Pro corrected Mistral Large by highlighting that the presence of endothelial markers does not negate a progenitor origin, as these progenitors are capable of aberrant differentiation.
• Mistral Large changed its vote to A after acknowledging the weight of the peer-reviewed evidence regarding dual-lineage marker expression.